Within the tumours from TCGA-SARC, LMS, UPS, and DDLPS were distributed across five of the six immune subtypes, with those allocated to the C3 (inflammatory) subgroup demonstrating a trend toward a longer progression-free interval and those in C3 or C2 (interferon-gamma (IFNγ)-dominant) subgroups showing some evidence of improved overall survival (OS). Here, IFNG is linked to neoplasm.